[Skip to Navigation]
Invited Commentary
May 2018

Value of Primary Data in Cost-effectiveness Analyses

Author Affiliations
  • 1Bernard and Shirlee Brown Glaucoma Research Laboratory, Edward S. Harkness Eye Institute, Department of Ophthalmology, Columbia University Medical Center, New York, New York
JAMA Ophthalmol. 2018;136(5):532-533. doi:10.1001/jamaophthalmol.2018.0653

Increasing health care costs have spurred the growth of cost-effectiveness analysis (CEA), which is a method of analysis that compares the value of health care gains relative with a comparator. Clinicians, policy makers, payers, and patients have a vested interest in ensuring the publication of high-quality economic evaluations of novel diagnostic or therapeutic approaches. In this issue of JAMA Ophthalmology, Stroupe et al1 have conducted a randomized clinical trial–based cost-effectiveness evaluation of a visual rehabilitation program. The authors report that, compared with low-vision services, vision rehabilitation in a US Department of Veterans Affairs system delivers improved functional visual outcomes at a similar cost.

Add or change institution